Lincoln Pharmaceuticals Management
Management criteria checks 3/4
Lincoln Pharmaceuticals' CEO is Mahendrabhai Patel, appointed in Jun 2018, has a tenure of 6.5 years. total yearly compensation is ₹4.93M, comprised of 99.4% salary and 0.6% bonuses, including company stock and options. directly owns 6.52% of the company’s shares, worth ₹1.06B. The average tenure of the management team and the board of directors is 6.1 years and 10.1 years respectively.
Key information
Mahendrabhai Patel
Chief executive officer
₹4.9m
Total compensation
| CEO salary percentage | 99.4% |
| CEO tenure | 6.5yrs |
| CEO ownership | 6.5% |
| Management average tenure | 6.1yrs |
| Board average tenure | 10.1yrs |
Recent management updates
Recent updates
Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified
Dec 05
Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Are Of Questionable Quality
Nov 23Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be Increased To ₹1.80
Sep 08Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?
Sep 06Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market
Mar 14Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Nov 04Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 14Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50
Aug 31Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 12Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50
Aug 29If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late
Feb 14Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?
Aug 16Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock
May 06Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?
Apr 03Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?
Mar 15Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?
Feb 28Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares
Feb 12Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Feb 01
Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years
Jan 19Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹966m |
| Jun 30 2024 | n/a | n/a | ₹980m |
| Mar 31 2024 | ₹5m | ₹5m | ₹933m |
| Dec 31 2023 | n/a | n/a | ₹873m |
| Sep 30 2023 | n/a | n/a | ₹808m |
| Jun 30 2023 | n/a | n/a | ₹769m |
| Mar 31 2023 | ₹3m | ₹3m | ₹729m |
| Dec 31 2022 | n/a | n/a | ₹714m |
| Sep 30 2022 | n/a | n/a | ₹674m |
| Jun 30 2022 | n/a | n/a | ₹667m |
| Mar 31 2022 | ₹3m | ₹3m | ₹694m |
| Dec 31 2021 | n/a | n/a | ₹709m |
| Sep 30 2021 | n/a | n/a | ₹668m |
| Jun 30 2021 | n/a | n/a | ₹647m |
| Mar 31 2021 | ₹3m | ₹3m | ₹623m |
| Dec 31 2020 | n/a | n/a | ₹586m |
| Sep 30 2020 | n/a | n/a | ₹560m |
| Jun 30 2020 | n/a | n/a | ₹540m |
| Mar 31 2020 | ₹2m | ₹2m | ₹514m |
| Dec 31 2019 | n/a | n/a | ₹510m |
| Sep 30 2019 | n/a | n/a | ₹492m |
| Jun 30 2019 | n/a | n/a | ₹453m |
| Mar 31 2019 | ₹2m | ₹2m | ₹487m |
| Dec 31 2018 | n/a | n/a | ₹470m |
| Sep 30 2018 | n/a | n/a | ₹495m |
| Jun 30 2018 | n/a | n/a | ₹458m |
| Mar 31 2018 | ₹2m | ₹2m | ₹346m |
Compensation vs Market: Mahendrabhai's total compensation ($USD57.93K) is below average for companies of similar size in the Indian market ($USD173.81K).
Compensation vs Earnings: Mahendrabhai's compensation has increased by more than 20% in the past year.
CEO
Mahendrabhai Patel (70 yo)
6.5yrs
Tenure
₹4,925,000
Compensation
Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd since June 08, 2018. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 6.5yrs | ₹4.93m | 6.52% ₹ 1.1b | |
| Chief Financial Officer | 5.8yrs | ₹1.32m | no data | |
| Company Secretary & Compliance Officer | 2.1yrs | ₹589.00k | no data | |
| Whole Time Director | no data | ₹6.64m | 11.63% ₹ 1.9b | |
| Whole Time Director | 29.9yrs | ₹3.81m | 1.87% ₹ 303.3m | |
| Whole Time Director | no data | ₹6.65m | 13.37% ₹ 2.2b | |
| Senior Manager of Operation | no data | no data | no data | |
| Vice President of Technical | no data | no data | no data | |
| Senior Manager of Planning & Administration | no data | no data | no data | |
| Group Marketing Manager | no data | no data | no data | |
| Sales and Distributor Head | no data | no data | no data | |
| Head of H R D | no data | no data | no data |
6.1yrs
Average Tenure
45.5yo
Average Age
Experienced Management: LINCOLN's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 29.9yrs | ₹4.93m | 6.52% ₹ 1.1b | |
| Whole Time Director | 10.1yrs | ₹6.64m | 11.63% ₹ 1.9b | |
| Whole Time Director | 29.9yrs | ₹3.81m | 1.87% ₹ 303.3m | |
| Whole Time Director | 10.1yrs | ₹6.65m | 13.37% ₹ 2.2b | |
| Non-Executive Director | 29.9yrs | no data | 3.78% ₹ 614.3m | |
| Non-Executive Chairman | 29.3yrs | no data | 2.39% ₹ 388.3m | |
| Independent Non-Executive Director | 6.8yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Woman Independent Director | less than a year | no data | no data |
10.1yrs
Average Tenure
64yo
Average Age
Experienced Board: LINCOLN's board of directors are seasoned and experienced ( 10.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 04:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kameswari V. S. Chavali | FirstCall Research |